PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 9 Publications

5 Customer Reviews

  • (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

    Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

  • C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

    Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 M1;3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXJTWM2OD1yLkiyNFI1KM7:TR?= M1j0SHNCVkeHUh?=
UACC-893 M3;qT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PoSGlEPTB;NT6xPVg5PiEQvF2= M{X5ZXNCVkeHUh?=
A427 M17Ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnCe3hKSzVyPUWuO|I2PjdizszN MUfTRW5ITVJ?
OCUB-M NXnDfldyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZwNk[xNFIh|ryP MWPTRW5ITVJ?
SW684 NIfSVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjIcWlKSzVyPUeuOVIzPjhizszN Moq5V2FPT0WU
SK-LMS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnySolKSzVyPUmuNFE{ODJizszN NVzu[YtrW0GQR1XS
CP50-MEL-B MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTlwM{C0NVkh|ryP MofPV2FPT0WU
NCI-H1651 M{XxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle3TWM2OD1zMD6wNlc3KM7:TR?= Mk\3V2FPT0WU
ABC-1 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Lv[GlEPTB;MUCuNVA{PyEQvF2= MVzTRW5ITVJ?
OE19 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPSTWM2OD1zMD6xO|M{KM7:TR?= MVvTRW5ITVJ?
DSH1 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFyLki4O|kh|ryP NUL0RmZlW0GQR1XS
SW13 NVr2bItkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;pXWlEPTB;MUGuPVMyQSEQvF2= M4DT[3NCVkeHUh?=
MDA-MB-453 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF{LkG2NFMh|ryP NFzUOYVUSU6JRWK=
647-V NWnD[4ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjBTGFLUUN3ME2xNk4{PTh{IN88US=> Mn7YV2FPT0WU
NCI-H2342 M17p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf1UYJKSzVyPUGyMlM6QTVizszN MVHTRW5ITVJ?
LB2241-RCC NGj4dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvaWYFRUUN3ME2xNk42Pzd7IN88US=> MlPTV2FPT0WU
UACC-257 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTF|LkS0OVMh|ryP M33aNnNCVkeHUh?=
NCI-H661 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PBZWlEPTB;MUOuOlQ1QSEQvF2= MojVV2FPT0WU
FADU NX36OXBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF|Lk[5PVIh|ryP NYqycVlLW0GQR1XS
A2780 NVrWN5hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHPTWM2OD1zMz64NFQyKM7:TR?= M1TNfXNCVkeHUh?=
NCI-H1793 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF2LkSwPFUh|ryP MoXNV2FPT0WU
TE-8 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLlPGNKSzVyPUG1MlM1PjVizszN MmT6V2FPT0WU
HGC-27 MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPKTWM2OD1zNj6xOlQ1KM7:TR?= NXK4PVlsW0GQR1XS
MMAC-SF MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X0NmlEPTB;MUeuN|czPyEQvF2= M{fIfHNCVkeHUh?=
Calu-6 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[4bHVKSzVyPUG4MlE2OTNizszN M3vKSHNCVkeHUh?=
HUTU-80 M3nVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHZUnB6UUN3ME2xPE4{QTV7IN88US=> M1nuT3NCVkeHUh?=
SAS NYe2cJhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jyfGlEPTB;MUiuOlQ2PSEQvF2= MXzTRW5ITVJ?
IST-MES1 M2rH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF6Lk[1NFgh|ryP Ml7IV2FPT0WU
C3A NGHlTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrKUItCUUN3ME2xPE44QTF7IN88US=> NGLsW4NUSU6JRWK=
ES3 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLySZdKSzVyPUG4Mlg{PjRizszN MlvpV2FPT0WU
HSC-2 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnDUlR4UUN3ME2xPU43PTRzIN88US=> M{LofXNCVkeHUh?=
T47D NXfu[INMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\sTWM2OD1{MD6xOFg2KM7:TR?= MliwV2FPT0WU
EW-7 M4DOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWwTWM2OD1{MD64OVg5KM7:TR?= M4\MNnNCVkeHUh?=
LN-405 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf6XFFKSzVyPUKwMlg6PjVizszN MnHIV2FPT0WU
U031 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL1XIxKSzVyPUKxMlQ5ODJizszN NGTj[WJUSU6JRWK=
A549 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvCXWZKSzVyPUKxMlg1QTFizszN MkeyV2FPT0WU
RMG-I Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLhTWM2OD1{Mj6yOlY5KM7:TR?= M1jMVHNCVkeHUh?=
BT-474 NXTkUJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD1{Mj62OVUyKM7:TR?= M3XWPXNCVkeHUh?=
NB69 M3myVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTtTWM2OD1{Mz6xOVIh|ryP MkO2V2FPT0WU
NB7 M{K0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XmXWlEPTB;MkSuNVg5KM7:TR?= MWTTRW5ITVJ?
HCC1569 NYX1[FZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJ2Lk[xNlUh|ryP NX\oOWpOW0GQR1XS
MEL-JUSO MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTwSYU4UUN3ME2yOE43QTB6IN88US=> MVfTRW5ITVJ?
MDA-MB-175-VII M1L6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TDS2lEPTB;MkWuNlUyPyEQvF2= NFHQR2tUSU6JRWK=
HCC1419 NXHS[opwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfaSFNKSzVyPUK1MlYxODNizszN MlHuV2FPT0WU
Ca9-22 NWnCNZc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnCOG17UUN3ME2yOU43PDN{IN88US=> M4nNZXNCVkeHUh?=
KGN MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjLS4tSUUN3ME2yOU44PTR5IN88US=> NGLHeXJUSU6JRWK=
LB373-MEL-D NIHLV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ4LkG5N|gh|ryP NUjZTYtDW0GQR1XS
NCI-H1755 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ4Lki4OFEh|ryP M3vqPHNCVkeHUh?=
D-423MG MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLEXmhFUUN3ME2yO{4xPzF3IN88US=> NWfBPVM5W0GQR1XS
DK-MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTJ6Lke4OFYh|ryP MnLZV2FPT0WU
NCI-H1623 M1;2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vOZmlEPTB;MkiuPFM1OiEQvF2= NXLIcFc2W0GQR1XS
KU-19-19 NIXwZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3zTWM2OD1{OD65PVUh|ryP MXnTRW5ITVJ?
C-33-A MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TNRmlEPTB;MkmuNlE6QCEQvF2= Mn72V2FPT0WU
SCC-4 MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfCOnlpUUN3ME2zNE4{OzV2IN88US=> MkW2V2FPT0WU
MG-63 NWPacFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37odWlEPTB;M{CuOVk6PCEQvF2= MmOzV2FPT0WU
LNCaP-Clone-FGC M{H5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[wfJRlUUN3ME2zNU41QTJzIN88US=> NITZe5pUSU6JRWK=
CAPAN-1 NVLMcno3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIC4RpJKSzVyPUOxMlUzQDZizszN M{TCcnNCVkeHUh?=
GI-ME-N M{S2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETQSZpKSzVyPUOxMlU{PTNizszN NIe5XYJUSU6JRWK=
RERF-LC-MS NG[4Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN{Lk[3OFch|ryP NXX6WmJMW0GQR1XS
KLE NWG2eINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTZTWM2OD1|Mz60N|M1KM7:TR?= NEjzTpFUSU6JRWK=
KNS-81-FD NWjkT3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX6cW1NUUN3ME2zN{42ODB6IN88US=> MWfTRW5ITVJ?
DOK NVT5cIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6yc|NOUUN3ME2zOE43PjF{IN88US=> NXX3fpM4W0GQR1XS
ACHN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3uTWM2OD1|NT6xOVg5KM7:TR?= M4rnbHNCVkeHUh?=
KYSE-520 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnkO3RKUUN3ME2zOU4zOzZzIN88US=> NIWyPHlUSU6JRWK=
SBC-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\F[mlEPTB;M{WuOVEyPiEQvF2= MYDTRW5ITVJ?
NCI-H28 MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHKR3huUUN3ME2zOU43Pjl3IN88US=> NVzrdohFW0GQR1XS
ES7 Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTN4LkKyOFkh|ryP NYrmT4ZYW0GQR1XS
A172 NUjPfG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrXTWM2OD1|Nj60NVg4KM7:TR?= Ml3WV2FPT0WU
UM-UC-3 M2HSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzsTWM2OD1|Nz64O|Q3KM7:TR?= M{PiUHNCVkeHUh?=
LXF-289 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTrcmRKSzVyPUO4MlAxPDdizszN MkjIV2FPT0WU
KP-4 M33GNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;oZoFRUUN3ME2zPE41PzN7IN88US=> NX3RS2pNW0GQR1XS
TE-1 NWPHfG16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv3OlR1UUN3ME2zPU43PTh7IN88US=> MojhV2FPT0WU
G-402 NGjSVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLUWZV6UUN3ME20NE4xPjFizszN M4PxfHNCVkeHUh?=
786-0 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjnXGFKSzVyPUSwMlkxQTZizszN M1nrfnNCVkeHUh?=
K5 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRzLkO2PFYh|ryP NILCXFRUSU6JRWK=
SK-N-DZ NI\sOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHmcnhMUUN3ME20NU4{QDJ|IN88US=> NYrM[G0zW0GQR1XS
OVCAR-4 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Thc2lEPTB;NEGuO|U3QCEQvF2= NHzpbHZUSU6JRWK=
T84 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTR{LkGyOlMh|ryP MkTyV2FPT0WU
GCIY MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXO[IcyUUN3ME20N{4xQDB|IN88US=> M2XBfnNCVkeHUh?=
BB49-HNC Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fMfGlEPTB;NEOuN|M1QCEQvF2= MYjTRW5ITVJ?
SNU-C2B M2DzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHVUI9KSzVyPUSzMlY1OzZizszN NIrEc|ZUSU6JRWK=
TE-6 NUKyWVZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DtOmlEPTB;NEOuPFg6PCEQvF2= NGrDPJRUSU6JRWK=
23132-87 NU\iPVFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G5fWlEPTB;NESuNlk4QCEQvF2= MmSwV2FPT0WU
DMS-53 M{HsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D6SmlEPTB;NESuN|M5PCEQvF2= MkCyV2FPT0WU
ONS-76 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK4TWM2OD12ND63OlYyKM7:TR?= NH3NdINUSU6JRWK=
DMS-273 NF;4XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnoNXdEUUN3ME20OE46PDNizszN MmHIV2FPT0WU
COLO-824 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTR3Lki3O|Uh|ryP NIP6XHNUSU6JRWK=
DMS-114 NWDLcZI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\UXmJKSzVyPUS1Mlg6OjdizszN NUPOeGtlW0GQR1XS
YKG-1 M{TiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml21TWM2OD12Nj6wN|U2KM7:TR?= MYnTRW5ITVJ?
RH-18 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLJTWM2OD12Nj6zO|M{KM7:TR?= Mn3mV2FPT0WU
NCI-H1355 NV3Fe4VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi2[YJKSzVyPUS2MlYyQCEQvF2= MU\TRW5ITVJ?
NCI-H2170 M1fDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTR5Lke1PFQh|ryP MYrTRW5ITVJ?
OC-314 NFHVcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LpV2lEPTB;NEeuPFQ4QCEQvF2= M{PqXXNCVkeHUh?=
NCI-H2030 M2nYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTR5Lki5NFYh|ryP M2nkcXNCVkeHUh?=
22RV1 M2jkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHJN|Q5UUN3ME20O{46ODF3IN88US=> NEPnT5pUSU6JRWK=
G-401 Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWwTWM2OD12OD60OFE2KM7:TR?= NUS0T|BRW0GQR1XS
YAPC NVrDUo1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LZPGlEPTB;NEmuPFA4OyEQvF2= MofvV2FPT0WU
SW1573 NUOzd5BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PWVmlEPTB;NUCuNlQ{PSEQvF2= NYDlU3VKW0GQR1XS
COLO-792 NU[wVGVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[yVmlEPTB;NUCuOlI{PyEQvF2= M4TDeHNCVkeHUh?=
KNS-62 NHvGSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXaTWM2OD13MD63OVA5KM7:TR?= NF7EOJZUSU6JRWK=
NB5 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF23fWJKSzVyPUWxMlQ2ODlizszN MUnTRW5ITVJ?
CP66-MEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTVzLk[0NFgh|ryP M1LQc3NCVkeHUh?=
CaR-1 NETubnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\Qe2lEPTB;NUKuNFYxPiEQvF2= NIDrfYtUSU6JRWK=
CAL-54 NFrsfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6zRYdKSzVyPUWyMlEyODJizszN NIXCcZJUSU6JRWK=
8305C M3XF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7DdWFUUUN3ME21Nk4{OTVizszN MVLTRW5ITVJ?
Calu-3 NFK4NGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\GTWM2OD13Mj6zO|M{KM7:TR?= MVvTRW5ITVJ?
AU565 NGDKfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTvNmZKSzVyPUWyMlU2ODlizszN M1q2O3NCVkeHUh?=
CW-2 NWPkdYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zqPWlEPTB;NUKuPFY2PCEQvF2= NGn1Z41USU6JRWK=
BEN NHTMV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFToVolKSzVyPUWzMlc5PjJizszN M1PBPHNCVkeHUh?=
NCI-H1975 M4nhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PmSmlEPTB;NUOuPFk3PiEQvF2= Mnr6V2FPT0WU
HCT-116 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzqXolKSzVyPUW0MlA{OjdizszN NWTZNZJCW0GQR1XS
SH-4 M1zPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHNVYQyUUN3ME21OE4yOzhizszN NWnuSZV3W0GQR1XS
NCI-H1693 NFvS[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq0TWM2OD13ND6yNVA{KM7:TR?= M{KydXNCVkeHUh?=
BPH-1 NIrnSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTQUZp7UUN3ME21OU4zQDl{IN88US=> NYPUWZB2W0GQR1XS
CAMA-1 M1fGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD13NT64NVE3KM7:TR?= M1iwPXNCVkeHUh?=
A388 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTqNFhKSzVyPUW2MlA6QDVizszN MnrFV2FPT0WU
C2BBe1 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PpNmlEPTB;NU[uNlY{PCEQvF2= NGKycmlUSU6JRWK=
GAMG NF3iRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjqXlRKSzVyPUW2MlU6PTVizszN MnTSV2FPT0WU
MKN28 NGLMe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTV4LkiwNVMh|ryP NGqyUFNUSU6JRWK=
VA-ES-BJ MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTaZYpKSzVyPUW2Mlg4PDVizszN MXLTRW5ITVJ?
HuCCT1 M4WxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;JSnZKSzVyPUW3MlA1QTJizszN NVrvOXFxW0GQR1XS
BFTC-905 NFfhfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnmTWM2OD13Nz6yPFk5KM7:TR?= MYPTRW5ITVJ?
LS-123 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTV5LkW2Olgh|ryP M{nUSXNCVkeHUh?=
LB996-RCC NGH5Zo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTV6LkCyPFch|ryP M3HNcXNCVkeHUh?=
NCI-H1048 NIfPO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXxTWM2OD13OD6yNVg5KM7:TR?= M2e4WXNCVkeHUh?=
COR-L105 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Kzb2lEPTB;NUiuO|M{PyEQvF2= M3\WeHNCVkeHUh?=
OVCAR-8 NV;ONI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfDR2xKSzVyPUW5MlE4OTZizszN NWTkfZdFW0GQR1XS
SK-N-FI NFPVb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTMSHFNUUN3ME21PU4{OjB5IN88US=> MYjTRW5ITVJ?
MES-SA NEHJNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTV7LkS1NFkh|ryP MUjTRW5ITVJ?
SCC-9 M1\vOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorDTWM2OD13OT60O|U{KM7:TR?= MlW5V2FPT0WU
EFO-27 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS4TlI5UUN3ME21PU46PDNizszN MlS4V2FPT0WU
GT3TKB MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPq[FNKSzVyPU[wMlYxPDhizszN NEjiVXhUSU6JRWK=
HCC38 M1jzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfaTWM2OD14MT60N|c6KM7:TR?= MlrBV2FPT0WU
MLMA M2nIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LYUmlEPTB;NkGuOlE3OyEQvF2= M1TkVnNCVkeHUh?=
D-566MG NHywOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTZ|LkWyNlQh|ryP MXrTRW5ITVJ?
SF295 M3PGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZ|Lk[2OVUh|ryP MWDTRW5ITVJ?
ES4 NV;Vb|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf2b5ByUUN3ME22OE41PzF7IN88US=> NHT6T5FUSU6JRWK=
CAKI-1 M2HXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTZ2LkW3NlEh|ryP NVHOTHd5W0GQR1XS
OAW-28 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZ2Lkm2OFch|ryP NWHHVVZXW0GQR1XS
NCI-H460 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfCTWM2OD14NT6wPFk4KM7:TR?= NVzTUlNlW0GQR1XS
JAR NHTZVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnftTWM2OD14NT61OVE3KM7:TR?= MU\TRW5ITVJ?
SNU-449 M2i4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;lVlE2UUN3ME22OU44PjF4IN88US=> NVrGe4pZW0GQR1XS
D-392MG NFrMU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPZeJBVUUN3ME22OU46PDN2IN88US=> NVTpbI5CW0GQR1XS
EW-22 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;OTWM2OD14Nj6zPVUh|ryP M2DTXXNCVkeHUh?=
GCT MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXodYhKSzVyPU[3MlA1PDNizszN NXzFdG5uW0GQR1XS
NOS-1 M3jxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTZ5Lk[4Olch|ryP NIq4dGtUSU6JRWK=
RH-1 NVS2dINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjRR2tKSzVyPU[4MlU2PTlizszN MlrvV2FPT0WU
HuH-7 NIXDdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZ7LkGwNFIh|ryP MoXEV2FPT0WU
NUGC-3 NEXlTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T6S2lEPTB;N{CuPVY1PCEQvF2= NV7rb4JkW0GQR1XS
IST-SL1 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTNVY1UUUN3ME23NU4zOzJ2IN88US=> M2XtR3NCVkeHUh?=
SHP-77 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLOWohKSzVyPUeyMlEyQSEQvF2= NYjQUXVjW0GQR1XS
SW1116 NEGwZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLMTWM2OD15Mj6xOFA4KM7:TR?= NHjSR5pUSU6JRWK=
LK-2 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTd{Lki2NVIh|ryP MW\TRW5ITVJ?
U-2-OS M4rZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTd|LkG4Nlgh|ryP M2Pze3NCVkeHUh?=
KYSE-150 NViwSZlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTTWmV5UUN3ME23N{43OTF6IN88US=> NEnHd29USU6JRWK=
U251 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTWe2NKSzVyPUezMlgyPjhizszN MkjoV2FPT0WU
HT-1080 NV7BNJZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTWNVZiUUN3ME23OE4zPTd2IN88US=> MXHTRW5ITVJ?
NCI-H1437 NHW0R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDvTWM2OD15ND62N|I3KM7:TR?= M2HMVHNCVkeHUh?=
HPAF-II NXnHSW1MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTd2Lk[0NVUh|ryP NYrWUFdiW0GQR1XS
Becker MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrPbmt4UUN3ME23OU4yOTB3IN88US=> NFjjNlJUSU6JRWK=
PANC-10-05 M1rt[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzBT29KSzVyPUe1MlI5PjVizszN MWHTRW5ITVJ?
TYK-nu Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fhUWlEPTB;N{WuN|ExOiEQvF2= M1PzXXNCVkeHUh?=
SKG-IIIa MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnv1TWM2OD15NT6zN|QyKM7:TR?= MmjGV2FPT0WU
NCI-H1993 NX;WTI8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHjfoFKSzVyPUe1Mlc{QTdizszN NF;hNnlUSU6JRWK=
S-117 M2C3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:4TWM2OD15NT63OVUh|ryP NV\j[41EW0GQR1XS
HuO9 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDmb2J4UUN3ME23Ok4xODR6IN88US=> NEPFfHZUSU6JRWK=
CAL-51 NWPKSm9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XY[GlEPTB;N{[uNVAxPiEQvF2= M12we3NCVkeHUh?=
BT-20 NYGxSXZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnNTWM2OD15Nj6yNVY5KM7:TR?= MVnTRW5ITVJ?
LB831-BLC NUCwRm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\vTHNnUUN3ME23Ok4{OjF5IN88US=> NV\MVIU2W0GQR1XS
LB1047-RCC MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHGNYpQUUN3ME23Ok44PjF7IN88US=> MVfTRW5ITVJ?
ES8 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTd6LkCwO|Mh|ryP MWXTRW5ITVJ?
UMC-11 M4LJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfWcIhYUUN3ME23PE4xQDh2IN88US=> MlT4V2FPT0WU
NCI-H226 NWCyeYdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW4TWM2OD15OD6xN|E2KM7:TR?= NG\qO2hUSU6JRWK=
IGROV-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTd6LkW1OUDPxE1? M2LZVnNCVkeHUh?=
BHY NFfU[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3lc2lKSzVyPUe5MlU6PiEQvF2= NULRUnhqW0GQR1XS
MKN45 MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fmOGlEPTB;OECuN|E4PCEQvF2= NX7COmR7W0GQR1XS
IA-LM NFPIWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjlWGRKSzVyPUiwMlM2OTFizszN NGPGV4lUSU6JRWK=
WM-115 NYWxVpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRThzLkSxNVQh|ryP M2raV3NCVkeHUh?=
VMRC-RCZ NVfFTXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCzTWM2OD16MT60OFI2KM7:TR?= MlPLV2FPT0WU
NCI-H2291 M{PaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XmSmlEPTB;OEGuOlg1OiEQvF2= NGL0VZFUSU6JRWK=
MCF7 NYTyRYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2foWmlEPTB;OEOuNlg6PyEQvF2= NH7pWXNUSU6JRWK=
639-V M{PVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLmT3QzUUN3ME24OE43OTJ7IN88US=> M2LnPXNCVkeHUh?=
RT4 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjFO|VpUUN3ME24OU4zPDB|IN88US=> M3PQe3NCVkeHUh?=
NCI-H2405 NH6wUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoewTWM2OD16NT6yPVk4KM7:TR?= MVrTRW5ITVJ?
CAL-33 M4X2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e3c2lEPTB;OEWuOlMyPSEQvF2= NETodmxUSU6JRWK=
BT-549 NHuyTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrYPXVRUUN3ME24OU46Ozh{IN88US=> MW\TRW5ITVJ?
HT-1197 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\LWZZKSzVyPUi4MlExPzdizszN NH\tUIdUSU6JRWK=
G-361 NEDBOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXSTWM2OD16OD6xOFc1KM7:TR?= M32xUXNCVkeHUh?=
LS-411N M2n3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWzVFRKSzVyPUi5MlM{QDhizszN NEfNd3JUSU6JRWK=
HT-144 MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7wVZJyUUN3ME24PU42QTl{IN88US=> M1PqV3NCVkeHUh?=
DJM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTh7Lki4OFUh|ryP M1XF[3NCVkeHUh?=
CAL-12T NUi2fFdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHJXFlKSzVyPUmwMlc5QTVizszN M4jXPXNCVkeHUh?=
MKN7 NFXrOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\NTWM2OD17MT6zOVUyKM7:TR?= MYnTRW5ITVJ?
HuP-T3 M3rSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTl4LkGwNFQh|ryP MU\TRW5ITVJ?
SK-MG-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT4No81UUN3ME25Ok4yOzR6IN88US=> MWPTRW5ITVJ?
NCI-H2347 NUfMeHZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHwRXBYUUN3ME25PE4yODR{IN88US=> NWLMSHlkW0GQR1XS
SW872 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDtRW5KSzVyPUGwNE41PTZizszN MWPTRW5ITVJ?
COLO-829 NXLCeWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULmfYhHUUN3ME2xNFAvPTV|IN88US=> MnOwV2FPT0WU
MC-IXC NXvVOZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH6[G4yUUN3ME2xNFAvPjF3IN88US=> MmnzV2FPT0WU

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID